A Phase 1/2 Study to Evaluate the Safety Reactogenicity and Immunogenicity of Ad26.COV2.S Administered as a Heterologous Booster Vaccination in Adults 18 Years of Age and Older Following Single- or Two-Dose Vaccination With an Inactivated COVID-19 Vaccine
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Ad26.COV2 S (Primary) ; BBIBP CorV (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 15 Jun 2023 Results assessing safety and immunogenicity after 28 days of a single Ad26.COV2.S booster dose given at different intervals after 2 doses of BBIBP-CorV, published in the Vaccine.
- 11 Sep 2022 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
- 11 Sep 2022 Planned primary completion date changed from 1 May 2023 to 1 Dec 2023.